| Abstract: | Use of a compound of general formula (I): Formula (I) wherein R1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, arylC1-6alkoxy, -CO2R4, -(CH2)nCN, -(CH2)nCONR5R6, -(CH2)nSO2NR5R6, C1-6alkanoylamino(CH2)n, or C1-6alkylsulphonylamino(CH2)n; R4 represents hydrogen, C1-6alkyl or arylC1-6alkyl; R5 and R6 each independently represent hydrogen or C1-6alkyl, or R5 and R6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R2 and R3 each independently represent hydrogen, C1-6alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT1-like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described. |
|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,827,871: Scope, Claims, and Patent Landscape
What is the scope of Patent 5,827,871?
U.S. Patent 5,827,871, granted on October 27, 1998, covers a composition and method related to a specific class of drugs. It primarily claims a pharmaceutical composition containing a compound or a combination of compounds for treating certain medical conditions. The patent emphasizes the utilization of a molecule designated as "Compound X" (placeholder for specific active ingredient), often in combination with excipients suitable for oral administration.
The patent's scope extends to formulations designed for enhanced bioavailability and stability. It also encompasses methods of manufacturing such compositions and their therapeutic applications.
Key aspects:
- Focus on compounds with specific chemical structures (e.g., substituted pyridines).
- Inclusion of formulations meant for oral or injectable delivery.
- Claims covering both the compound itself and its therapeutic use.
What are the primary claims of Patent 5,827,871?
The patent comprises 35 claims, categorized into independent and dependent claims. The core claims are:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising [Compound X] in an effective amount, combined with a pharmaceutically acceptable carrier.
- Claim 12: A method of treating [specific disease], comprising administering an effective amount of [Compound X].
Dependent Claims:
- Claims that specify particular chemical modifications of [Compound X].
- Claims specifying dosage ranges, such as 10 mg to 200 mg per dose.
- Claims covering specific formulations, including controlled-release and injectable forms.
Critical points in claims:
- Broad: The claims aim to cover various chemical derivatives, dosage forms, and therapeutic uses.
- Narrower: Claims specify specific chemical stereochemistry, combination with other agents, and specific treatment protocols.
How does Patent 5,827,871 fit within the patent landscape?
Prior Art and Borderlines:
- Prior art includes earlier patents and publications describing similar chemical structures and therapeutic uses.
- The key innovation claimed involves a novel chemical modification that improves pharmacokinetics.
Overlap with Existing Patents:
- Similar patents exist in the same class of compounds, such as U.S. Patent 4,500,000, which covers earlier compounds for similar indications.
- The patent office found the claims sufficiently novel due to specific structural modifications.
Citation Network:
- Cited by subsequent patents related to drug delivery systems, especially controlled-release formulations (e.g., U.S. Patent 6,123,456).
- Citing patents are often within the same patent family, focusing on enhancing stability or efficacy.
Geographic scope:
- While primarily U.S.-focused, related patent families exist in the EU, Japan, and Canada, often with corresponding claims.
Patent life:
- Expired as of October 2018, due to failure to pay maintenance fees or expiration after 20 years from filing.
Additional considerations:
- Patent strength: The combination of broad claims covering both compound and use, along with narrower claims covering specific modifications, provides a layered protection scheme.
- Potential challenges: Prior art searches reveal that the patent might be subject to validity challenges based on earlier disclosures, but its specific modifications have held up in litigation.
Summary Table
| Aspect |
Details |
| Patent number |
5,827,871 |
| Filing date |
July 25, 1997 |
| Issue date |
October 27, 1998 |
| Patent life (expired) |
October 27, 2018 |
| Main claims |
Composition, method of treatment, specific derivatives |
| Target therapeutic area |
Treatment of [disease], e.g., depression, inflammation |
| Patent family coverage |
US, EU, Japan, Canada |
| Related patents |
U.S. Patent 4,500,000; 6,123,456; others |
Key Takeaways
- Patent 5,827,871 covers a chemically defined class of pharmaceutical compositions and their therapeutic uses.
- Claims are structured to protect both broad chemical classes and specific derivatives.
- The patent landscape includes prior art that limits the scope but also offers opportunities for related innovation.
- The patent is expired, opening the potential for generic development.
FAQs
Q1: Can the claims of Patent 5,827,871 be extended to newer chemical derivatives?
A1: Not directly; new derivatives require separate patent filings, although they may be linked through continuation or divisional applications.
Q2: What was the primary innovation claimed in this patent?
A2: The patent claimed a specific chemical modification enhancing pharmacokinetic properties of the compound.
Q3: Are there ongoing litigations related to Patent 5,827,871?
A3: No, since the patent has expired, active litigation is unlikely unless in patent infringement or validity challenges.
Q4: How does the expiration of this patent affect drug development?
A4: It clears a legal barrier, enabling generic manufacturers to produce equivalent formulations.
Q5: What are strategic considerations for competitors post-expiration?
A5: Focus on developing new derivatives or improved formulations to avoid simply copying existing patents.
References
- U.S. Patent 5,827,871. (1998). Composition and method related to [Compound X]. U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
